MoonLake Immunotherapeutics (MLTX) Q2 2025 earnings summary

Executive summary

• Focused on developing SLK/sonelokimab, a tri-specific IL-17A/F inhibiting Nanobody for inflammatory skin and joint diseases, with multiple ongoing Phase 3 and Phase 2 trials in HS, PSA, adolescent HS, PPP, and axSpA.

• No products approved or revenue generated; expects continued significant operating losses as clinical development and commercialization preparations progress.

• Robust financial position with $425.1 million in cash, cash equivalents, and short-term marketable securities as of June 30, 2025, expected to fund operations into 2028.

• Access to up to $500 million in non-dilutive financing, supporting growth initiatives and extending cash runway.

• Interim readout of Phase 2 LEDA trial in PPP delivered earlier than expected, further validating sonelokimab's potential.

Financial highlights

• Net loss for Q2 2025 was $56.1 million, up 126% year-over-year; six-month net loss was $96.6 million, up 149% year-over-year.

• Research and development expenses for Q2 2025 were $49.8 million, up 110% year-over-year; six-month R&D expenses were $86.2 million, up 135%.

• General and administrative expenses for Q2 2025 were $10.9 million, up 58% year-over-year; six-month G&A expenses were $22.0 million, up 60%.

• Net loss per share for Q2 2025 was $0.87, compared to $0.39 in Q2 2024 and $0.63 in Q1 2025.

• Operating loss for Q2 2025 was $60.7 million, compared to $47.5 million in Q1 2025.

Outlook and guidance

• Expects to submit a Biologics License Application for SLK/sonelokimab in 2026 and, pending FDA approval, anticipates first U.S. commercial launch in 2027.

• Primary endpoint readout for Phase 3 VELA program in HS expected around September 2025.

• Additional key clinical trial readouts expected through H1 2026, including PPP, axSpA, adolescent HS, and PSA.

• Operating losses expected to continue for at least the next two years as clinical programs and commercialization efforts advance.

• Cash runway extended into 2028, supporting planned product launch and further clinical development.